CJC-1295 + Ipamorelin 10 MG (5 MG + 5 MG)

### Synergistic Dual-Pathway Somatotropic Research Blend (CJC + IPA)

CJC-1295 + Ipamorelin (5 MG + 5 MG) combines Modified GRF 1-29 (CJC-1295 without DAC) and Ipamorelin in an equimolar single-vial 10 MG research formulation.

Designed to investigate the dual-pathway synergy between growth hormone-releasing hormone (GHRH) receptor activation and ghrelin receptor (GHS-R) agonism simultaneously.

### Research Synergy

• **Dual Receptor Co-Activation**: GHRHR and GHS-R1a cross-talk in pituitary cellular lines.

• **Pulsatile Secretion Dynamics**: Investigates amplified cellular responsiveness compared to either peptide in isolation.

• **Protein Synthesis Modeling**: Applied in musculoskeletal cellular turnover and nitrogen retention assays.

### Specifications

• **Composition**: 5 MG CJC-1295 (Mod GRF 1-29) + 5 MG Ipamorelin

• **Total Peptide Content**: 10 MG per vial

• **Combined Purity**: ?98.5% (Dual-peak HPLC resolved)

• **Endotoxin Level**: <0.5 EU/mg

### Storage Instructions

• Store lyophilized powder at -20??C.

• After reconstitution, store refrigerated at 2??C-8??C. Utilize within 21 to 28 days.